Publications by authors named "Peter Lebowitz"

Claim this Profile
E
Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.
Suzanne Edavettal, Pilar Cejudo-Martin, Bidisha Dasgupta, Danlin Yang, Matthew D Buschman, Peter F Lebowitz

Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving upstream in anticancer drug development.
William N Hait, Peter F Lebowitz

Nat Rev Drug Discov· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, Greg Curt, Mace Rothenberg, Peter Lebowitz

Lancet Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Interception: Myths, Mountains, and Mole Hills.
William N Hait, Peter F Lebowitz

Cancer Prev Res (Phila)· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, Kevin B Kim, H-Tobias Arkenau, Peter Lebowitz

Clin Cancer Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
Katherine L Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, Joel Greshock, Richard Letrero, Peter F Lebowitz

Clin Cancer Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
Matteo S Carlino, Catherine A B Saunders, Lauren E Haydu, Alexander M Menzies, C Martin Curtis, Peter F Lebowitz

Eur J Cancer· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Keith T Flaherty, Jeffery R Infante, Adil Daud, Rene Gonzalez, Richard F Kefford, Peter Lebowitz

N Engl J Med· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Gerald S Falchook, Karl D Lewis, Jeffrey R Infante, Michael S Gordon, Nicholas J Vogelzang, Peter F Lebowitz

Lancet Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, Kevin B Kim, Tobias H Arkenau, Peter Lebowitz

Lancet· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
John W Bauman, Joyce M Antal, Laurel M Adams, Brendan M Johnson, Sharon C Murray, Peter F Lebowitz

Invest New Drugs· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine.
Joanna D Holbrook, Joel S Parker, Kathleen T Gallagher, Wendy S Halsey, Ashley M Hughes, Peter F Lebowitz

J Transl Med· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
Brendan M Johnson, Laurel M Adams, Ke Zhang, Shelby D Gainer, Lyndon C Kirby, Peter F Lebowitz

J Clin Pharmacol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
Kelly K Curtis, Jean T Hartney, Roxanne C Jewell, Jung W Park, Peter F Lebowitz

J Clin Pharmacol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
Larissa A Korde, Lara Lusa, Lisa McShane, Peter F Lebowitz, LuAnne Lukes

Breast Cancer Res Treat· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.
Laurel M Adams, Brendan Johnson, Ke Zhang, Lin Yue, Lyndon C Kirby, Peter Lebowitz

Support Care Cancer· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
Brendan Johnson, Laurel Adams, Emily Lu, Ke Zhang, Peter Lebowitz

Support Care Cancer· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Anna Maria Storniolo, Mark D Pegram, Beth Overmoyer, Paula Silverman, Nancy W Peacock, Peter F Lebowitz

J Clin Oncol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.
Amy Rapkiewicz, Virginia Espina, Jo Anne Zujewski, Peter F Lebowitz, Armando Filie

Cancer· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Carter Van Waes, Angela A Chang, Peter F Lebowitz, Colleen H Druzgal, Zhong Chen

Int J Radiat Oncol Biol Phys· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Peter F Lebowitz, Jennifer Eng-Wong, Brigitte C Widemann, Frank M Balis, Nalini Jayaprakash

Clin Cancer Res· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Peter F Lebowitz, Jennifer Eng-Wong, Sandra M Swain, Arlene Berman, Maria J Merino

Clin Cancer Res· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hormonal therapy of breast cancer.
Peter F Lebowitz, JoAnne Zujewski

Curr Probl Cancer· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis